An increased AKR1B10 expression was associated with a poorer prognosis in oral squamous cells, gastric carcinomas, and lung adenocarcinomas [39,41,50,51] whereas a decreased AKR1B10 expression was associated with a significantly worse survival in colorectal cancer [52]. Here, AKR1B10 is linked to gastric carcinoma.